UNIVERSITY PARK, Pa. — Joseph J. Doncsecz, partner vp for finance and company controller for Penn State, has been named the College of Medicine’s interim accomplice vp for finance and commercial enterprise, effective Aug. 1.
Doncsecz takes over for Eric Strucko, who became senior vp and chief financial officer of the Milton S. Hershey Medical Center and Penn State Health Medical Group on July 1. The University will launch a national seeks to fill the role.
“Joe Doncsecz is a highly skilled and widely reputable economic administrator who’s very conversant with the desires and issues facing each the College of Medicine and Penn State Health,” stated David Gray, senior vice president for finance and enterprise and treasurer for Penn State. Gray added that Doncsecz became instrumental in guiding the latest change approved by using the Board of Trustees to allow Penn State Health to problem debt in its call, which is intended to strengthen the sustainability of help for the College of Medicine.
“Joe’s extensive finance and business experience, in addition to his deep expertise of the University’s task and operations, will assist the continuing boom and balance of our College of Medicine throughout this time of transition,” said Kevin Black, period in-between dean of the College of Medicine. “I am grateful for his willingness to serve on this role even as we conduct a national search for an everlasting associate vice chairman for finance and commercial enterprise.”
As partner vice president for finance, Doncsecz provides routine reviews to the Board of Trustees’ Committee on Audit and Risk and the Committee on Finance, Business, and Capital Planning. In his role as company controller, he oversees Penn State’s machine of internal controls; allows all external economic and accounting manipulate audits; and leads the University’s cash, debt, and threat control functions, along with coordination of all cash receipts and disbursements according to with Penn State’s running and capital finances plans and rules. Donchez’s company obligations additionally encompass monetary, accounting, and treasury advisory roles with the Milton S. Hershey Medical Center, Penn State Health, the Penn State Research Foundation, and the Penn State Investment Council.
He has helped lead the effort to update the University’s legacy Integrated Business Information System, or IBIS, with the launch and implementation of the new System for Integrated Management, Budgeting and Accounting (SIMBA), scheduled to move on July 1, 2020. Despite his new interim function on the College of Medicine, Doncsecz will remain a sponsor of the SIMBA effort. He additionally serves as assistant treasurer of the Corporation for Penn State, treasurer for the Pennsylvania College of Technology. He holds various officer and licensed signatory roles for the University’s subsidiary corporations.
Susan Wiedemer, associate controller and assistant treasurer at Penn State, might be between associate vp for finance and corporate controller in Doncsecz’s absence. Gray said of Wiedemer, “Sue is a pro monetary chief who has been instrumental in helping Penn State’s cash, debt, and ordinary economic control software. She will do an excellent job main the Corporate Controller’s workplace until Joe can return.” Kurt Kissinger, associate vice president for finance and commercial enterprise at Penn State and former director of operations at the College of Medicine, serves in a performing ability at the college until Doncsecz officially assumes his responsibilities on Aug. 1.
Listen carefully the following time you hear medical “experts” whining that a substance or method has now not been “scientifically” evaluated in a double-blind look at and is consequently now not but “demonstrated” effective. They’re just looking to mislead and intimidate you. Ask them how a good deal of “clinical” proof underlies the usage of chemotherapy and radiation for most cancers or angioplasty for coronary heart disease. The reality is, it’s very little. Try turning the scenario around. The specialists demand that they scientifically show the efficacy of a number of their cash cows, consisting of chemotherapy and radiation for cancer, angioplasty and skip for heart disease, or hysterectomies for uterine problems. The efficacy hasn’t been demonstrated because it cannot be confirmed.
There is no need in any way for practitioners and customers of opportunity medicine to wait like supplicants with hat in hand for the medical “experts” of traditional remedy to dole out some condescending scraps of reliable popularity of opportunity tactics. Rather, discerning citizens need to disturb those experts that show the science behind their medication via demonstrating successful, dependable, and cheap affected person outcomes. If they can not, those strategies need to be rejected for being unscientific. After all, the proof is within the treatment.
